EFNA2 and glioblastoma: For example, chimeric antigen receptor T cells simultaneously targeting HER2, IL13Rα2, and ephrin-A2 have been reported to overcome antigenic heterogeneity and lead to improved treatment outcomes in IDH wild-type glioblastoma (34,35).